Pracinostat dihydrochloride is a small molecule inhibitor primarily known for its role as a histone deacetylase (HDAC) inhibitor, which is significant in the field of cancer research and treatment. It is characterized by its ability to modulate gene expression by altering the acetylation status of histones, thereby influencing cellular processes such as proliferation, differentiation, and apoptosis. The compound is typically presented as a dihydrochloride salt, enhancing its solubility and stability in aqueous solutions, which is beneficial for pharmacological applications. Pracinostat has been investigated in various clinical trials, particularly in combination therapies for hematological malignancies and solid tumors. Its mechanism of action involves the reactivation of tumor suppressor genes and the induction of cell cycle arrest and apoptosis in cancer cells. As with many HDAC inhibitors, potential side effects may include gastrointestinal disturbances and hematological changes, necessitating careful monitoring during therapeutic use. Overall, Pracinostat dihydrochloride represents a promising avenue in targeted cancer therapies, reflecting the ongoing efforts to develop more effective and selective treatment options.

Pracinostat Dihydrochloride is a potent histone deacetylase (HDAC) inhibitor with an IC50 of 40-140 nM, used in cancer research. It also inhibits the activity of metallo-β-lactamase structural domain-containing protein 2 (MBLAC2) hydrolase with an EC50 of less than 10 nM.

Pracinostat Dihydrochloride

929016-98-8: Pracinostat dihydrochloride is a small molecule inhibitor primarily known for its role as a histone deacetylase (HDAC) inhibitor, which is significant in the field of cancer research and treatment. It is characterized by its ability to modulate gene expression by altering the acetylation status of histones, thereby influencing cellular processes such as proliferation, differentiation, and apoptosis. The compound is typically presented as a dihydrochloride salt, enhancing its solubility and stability in aqueous solutions, which is beneficial for pharmacological applications. Pracinostat has been investigated in various clinical trials, particularly in combination therapies for hematological malignancies and solid tumors. Its mechanism of action involves the reactivation of tumor suppressor genes and the induction of cell cycle arrest and apoptosis in cancer cells. As with many HDAC inhibitors, potential side effects may include gastrointestinal disturbances and hematological changes, necessitating careful monitoring during therapeutic use. Overall, Pracinostat dihydrochloride represents a promising avenue in targeted cancer therapies, reflecting the ongoing efforts to develop more effective and selective treatment options.

Pracinostat dihydrochloride is a highly effective histone deacetylase (HDAC) inhibitor with IC₅₀ values ranging from 40 to 140 nM, utilized in cancer research. Additionally, it inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ of less than 10 nM.

CAS 929016-98-8

Pracinostat Dihydrochloride

Pracinostat dihydrochloride

Ref: TM-T88235